980P Phase Ib Study of a Liposomal Formulation of Eribulin (E7389-LF) + Nivolumab (nivo) in Patients (pts) with Advanced Solid Tumors

N. Yamamoto, H. Ida, T. Shimizu,Y. Nakamura,M. Nishino,S. Yazaki,Y. Katsuya,J. Sato,T. Koyama,S. Iwasa,K. Sudo,S. Kondo,K. Yonemori, S. Shiono, T. Suzuki,T. Takase, S. Takashima, K. Yamaguchi,T. Semba,K. Shitara

Annals of oncology（2021）

引用 1|浏览20

暂无评分

摘要

Eribulin is a halichondrin-class microtubule dynamics inhibitor with cytotoxic and vascular remodeling effects leading to tumor immune modulation. E7389-LF is a liposomal formulation of eribulin designed to enhance antitumor activity and improve pharmacokinetic (PK) profiles. The combination of E7389-LF + Nivo is expected to show antitumor activity by cytotoxic and antitumor immune effects.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要